Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SRRK | US
-0.03
-0.39%
Healthcare
Biotechnology
31/03/2024
05/07/2024
7.74
7.71
7.83
7.53
Scholar Rock Holding Corporation a biopharmaceutical company focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181 which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases including neuromuscular disorders cancer fibrosis and iron-restricted anemia. The company has a collaboration agreement with Gilead Sciences Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge Massachusetts.
View LessNegative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
56.8%1 month
49.1%3 months
58.4%6 months
69.3%-
-
4.65
0.33
0.22
-4.92
8.22
-
-186.50M
617.30M
617.30M
-
-
-
-100.00
-89.09
14.91
37.98
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.61
Range1M
2.69
Range3M
8.29
Rel. volume
0.33
Price X volume
2.93M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
AnaptysBio Inc | ANAB | Biotechnology | 24.75 | 676.14M | -0.60% | n/a | 685.61% |
UroGen Pharma Ltd | URGN | Biotechnology | 15.88 | 653.15M | 5.80% | n/a | -246.69% |
Sage Therapeutics Inc | SAGE | Biotechnology | 10.78 | 648.76M | 1.51% | n/a | 0.47% |
Pliant Therapeutics Inc. | PLRX | Biotechnology | 10.52 | 634.63M | -0.57% | n/a | 12.50% |
Humacyte Inc | HUMA | Biotechnology | 5.27 | 627.57M | -7.05% | n/a | 71.00% |
Savara Inc | SVRA | Biotechnology | 4.43 | 612.18M | 2.31% | n/a | 21.80% |
GH Research PLC Ordinary Shares | GHRS | Biotechnology | 11.75 | 611.33M | -2.49% | n/a | 0.43% |
Lexicon Pharmaceuticals Inc | LXRX | Biotechnology | 1.67 | 603.69M | 0.60% | n/a | 36.78% |
PHATHOM PHARMACEUTICALS INC. | PHAT | Biotechnology | 10.3 | 602.91M | 0.49% | n/a | -315.85% |
Travere Therapeutics Inc. | TVTX | Biotechnology | 7.89 | 600.66M | -0.63% | n/a | 545.44% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Malibu Boats Inc | MBUU | Recreational Vehicles | 32.65 | 667.35M | -2.74% | n/a | 4.21% |
Ennis Inc | EBF | Building Products & Equipment | 21.25 | 552.16M | -0.75% | 13.68 | 1.15% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 4.48 | 428.47M | -2.40% | n/a | 138.85% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 25.77 | 412.92M | -1.68% | n/a | 322.60% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.74 | 369.15M | -2.49% | 14.12 | 86.68% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.36 | 324.63M | -2.40% | 10.10 | 0.00% |
Latham Group Inc. | SWIM | Building Products & Equipment | 2.74 | 316.67M | -3.52% | 75.75 | 80.81% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.55 | 298.02M | -0.34% | 8.24 | 25.57% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 26.52 | 294.97M | -4.29% | 17.47 | -562.47% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 12.93 | 209.56M | -2.78% | 8.94 | 15.44% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -4.92 | -2.43 | Cheaper |
Ent. to Revenue | 8.22 | 4,101.76 | Cheaper |
PE Ratio | - | 41.26 | - |
Price to Book | 4.65 | 22.34 | Cheaper |
Dividend Yield | - | 2.39 | - |
Std. Deviation (3M) | 58.37 | 76.52 | Lower Risk |
Debt to Equity | 0.33 | 0.51 | Cheaper |
Debt to Assets | 0.22 | 0.24 | Par |
Market Cap | 617.30M | 3.77B | Emerging |